Utilization of targeted therapies increased over time, however NHB patients were less likely to receive CDK4/6i compared to NHW. Approximately half of eligible patients did not receive pertuzumab. Further research is needed to understand mediators and design interventions to address underutilization of these therapies and those contributing to racial disparities in CDK4/6i utilization.
Martei et al. (Tue,) studied this question.